Author Manuscript
Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but dos not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Acute seizures in acute ischemic stroke: does thrombolysis have a role to play?

Vincent Alvarez MD, Andrea O. Rossetti MD, Vasileios Papavasileiou, MD & Patrik Michel MD

[1] Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland

Content:

Title: 79 characters (including spaces)

Abstract: 250 words

Text: 2236 words

3 Tables

3 Figures

36 references

Address correspondence to:

Dr Vincent Alvarez

Service de Neurologie

CHUV BH-07

CH-1011 Lausanne, Switzerland

Phone: +4121 314 11 11

Fax: +4121 314 12 90

E-mail : vincent.alvarez@chuv.ch

E-Mail address of authors:

- Andrea O. Rossetti: andrea.rossetti@chuv.ch
- Patrik Michel : patrik.michel@chuv.ch
- Vasileios Papavasileiou : vpapavasileiou@gmail.com

Key words: thrombolysis - rt-PA – neurotoxicity – epileptogenesis

Abstract:

Background: Seizures appear at stroke presentation, during acute phase or as late complication of stroke. Thrombolysis has not been investigated as a risk factor despite its potential neurotoxic effect. We try to identify risk factors for seizures during acute phase of ischemic stroke in a cohort including thrombolysed patients.

Methods: We undertook a case-control study at a single stroke center using data from Acute STroke Registry and Analyse of Lausanne (ASTRAL). Patients with seizure occurring during the first 7 days following stroke were retrospectively identified. Bi- and multivariable statistical analyses were applied to compare cases and randomly selected controls.

Results: We identified 28 patients experiencing from seizures in 2327 acute ischemic strokes (1.2%). All seizures occurred during the first 72 hours. Cortical involvement, thrombolysis with rt-PA, arterial recanalisation, and higher initial NIHSS were statistically associated with seizures in univariated analysis. Backward linear regression identified cortical involvement (OR 7.53, 95%-CI: 1.6 – 35.2, p<0.01) and thrombolysis (OR 4.6, 95%-CI: 1.6 – 13.4, p=0.01) as being independently associated with seizure occurrence. Overall, three months outcome measured by the modified Rankin Scale (mRS) was comparable in both groups. In the subgroup of thrombolysed patients, outcome was significantly worse at 3 months in the seizure group with 9/12 (75%) patients with mRS ≥ 3, compared to 6/18 (33.3%) in the seizure-free group (p=0.03).

Conclusions: Acute seizures in acute ischemic stroke were relatively infrequent. Cortical involvement and thrombolysis with rt-PA are the principal risk factors. Seizures have a potential negative influence on clinical outcome in thrombolysed patients.

Introduction

Stroke patients may experience epileptic seizures at stroke presentation, in the acute phase (commonly defined as the first 7 days) or as a late complication[1]. The incidence of post-stroke seizures varies between studies: 8.9% of patients suffering from ischemic or hemorrhagic stroke developed post-stroke epilepsy after nine months of follow-up[2] and 3.2% after seven years in another survey[3]. Reported seizure incidence during the acute phase of stroke was 6.3% during the first 24 hours in a mixed stroke population[4] and 14% during the first week after a hemorrhagic event[5]. Younger age[6], male gender[7], cortical involvement and a hemorrhagic component have consistently been found to be seizure predictors[7]. Thrombolysis has, to our knowledge, not been investigated as a risk factor for early seizures, despite its potential neurotoxic[8] and possible epileptogenic[9],[10] effects in animals.

The aim of our study was to identify risk factors for seizures during the acute phase of ischemic stroke in a large consecutive series of patients that included thrombolysed patients.

Methods

We undertook a case-control study at our tertiary care center. We used data from the Acute Stroke Registry and Analyse of Lausanne (ASTRAL)[11] containing all acute ischemic stroke arriving within 24 hours after last proof of good health at our center. Of note, all patients undergo continuous monitoring in our stroke unit for at least 24 hours and for a median of 54 hours and are then transferred to a standard hospital bed in the stroke unit. Demographics, stroke characteristics, laboratory and imaging data (acute perfusion CT in most patients, and subacute head CT or MRI in most patients) and clinical outcome data are collected prospectively. Patients whose main diagnosis was transient ischemic attack,

primary hemorrhagic stroke and cerebral venous thrombosis were excluded. The scientific use of the ASTRAL data was approved by the ethics commission for research on humans of the Canton of Vaud, subcommission III.

In ASTRAL, we retrospectively identified all patients with a seizure according to IALE & IBE definition[12] during the first 7 days following stroke, including first ever seizures or recurrent ones, by searching within the registry and by linking the ASTRAL patients to our EEG reports from January 1st 2004 until September 31st 2011 (93 Months). The EEG reports are standardized and include the reason for the study, detailed clinical and circumstantial description and antiepileptic medications used at the time of the exam.

As controls, we randomly selected 100 patients from ASTRAL without acute seizures during the same time period. Matching was not performed in order to avoid arbitrary exclusion of possible precipitating factors. The randomization was done using an EXCEL® table, adding an additional variable with the (=RAND) function. Patients were ranked according to this new variable. The first hundred patients were selected.

For each patient, time of seizure's occurrence, type of seizure according to the ILAE classification[13], and concomitant anti-epileptic treatment were recorded by reviewing the according medical files.

For case and control patients, all data concerning the stroke were extracted from ASTRAL. In particular, presence of previous stroke, statin use, and alcohol abuse were assessed. Laboratory data included acute glucose, sodium (Na+) and total cholesterol values. Acute stroke localization (involving the cortex or not), etiology according to the TOAST classification[14] plus dissection, NIHSS on admission, and use of iodine contrast for acute imagery were also assessed. Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) or acute endovascular treatments according to current

guidelines[15],[16], the presence of arterial occlusion on initial arterial imaging (mostly CT-angiography), partial or complete recanalisation at 12-48 hour follow-up imaging (CT- or MR-angiography or Doppler), and symptomatic hemorrhagic transformation according to the ECASS-II trial[17], and radiological hemorrhagic transformation according to the ECASS classification (when a control imagery was available) were also recorded. Finally, the modified Rankin Scale (mRS) at seven days and three months and mortality were obtained either during a follow-up visit at our stroke clinic or by phone by Rankin-certified medical personnel. Data not routinely registered in ASTRAL such as previous seizures, premorbid and post-stroke use of benzodiazepines and anti-epileptic drugs were obtained by reviewing all medical records.

Comparisons between the two groups were performed using two-tailed Fisher's exact, χ^2, Mantel-Haenszel χ^2, or t tests, as required. In order to adjust the results for possible confounders, the variables which were associated with seizure occurrence with a $p < 0.05$ in the univariate analysis were entered in a backward linear regression using acute seizure as dependant variable. Receiver operating characteristic (ROC) curves and area under the curves (AUC) were calculated for the different regression models. Patients who seized at stroke onset were excluded from bi- and multivariate analysis for factors associated with seizures' occurrence. Indeed in those patients, the outcome (seizure) precedes the exposition (potential thrombolysis). Analyses were performed with version 9 of the Stata software (College Station, TX).

Results

We identified 28 patients suffering from acute seizures in 2327 consecutive acute ischemic strokes (1.2%). All seizures occurred during the 72 hours of stroke onset and mostly so within the first 24 hours (figure 1). Eight (28.5%) patients had seizure at stroke onset. Of

these latter patients, only one received rt-PA (endovascular recanalisation with intra-arterial use of rt-PA), based on persisting focal deficits and focal hypoperfusion on CT-perfusion). The seven other patients with seizures at stroke onset were not thrombolysed. Most seizures were primarily generalized, followed by focal seizures with impairment of consciousness (figure 2). Among the 5 patients with status epilepticus, one had simple partial, two had complex partial and two had generalized status epilepticus. Of note, seizure's type distribution was the same in thrombolysed patients and in the non-thrombolysed ones (table 1).

Demographics, stroke features, and clinical outcomes are shown in table 2. Demographics were globally comparable. Also, there was no difference regarding premorbid treatment or for the presence of previous clinical stroke. Moreover, neither prevalence of previous seizures nor the premorbid use of anti-epileptic was different in both groups. Symptomatic and radiological hemorrhagic transformation occurred in comparable rates in both group. The admission metabolic values were also similar.

Several potential differences emerged in univariate analysis. Cortical involvement was significantly associated with seizures ($p<0.01$), as was thrombolysis with rt-PA ($p<0.01$). Seizure patients had a higher admission NIHSS ($p<0.01$) and had higher rates of recanalisation at follow-up imaging ($p<0.01$). Regarding stroke etiology, there were no global differences, but lacunar infarcts were completely absent in the seizure group. Radiological hemorrhagic transformation occurred non-significantly more frequently in the control group. Uncertainty regarding the precise time of stroke onset was non significantly more frequent in the control group.

Somewhat more patients in the seizure group tend to reach a poor functional outcome (mRS ≥3) at three months (Table 3). However, when analyzing the subgroup of thrombolysed patients only (Table 3), outcome was significantly worse at 3 months in the

seizure group, but there was no difference at seven days. Of note, in this subgroup analysis, the NIHSS was comparable with a median of 17.5 (+/- 5.7) in seizure group VS 16.6 (+/- 8.3) in the seizure-free one (p=0.56, t test). The rate of symptomatic hemorrhagic transformation was also the same with one patient in each group.

Backward linear regression including cortical involvement, NIHSS on admission, recanalisation thrombolysis identified cortical involvement (OR 7.53, 95%-CI: 1.6 – 35.2, p<0.01) and thrombolysis (OR 4.6, 95%-CI: 1.6 – 13.4, p=0.01) as being independently associated with seizure occurrence. The ROC curve for the different prediction models are shown in the figure 3. Cortical involvement and thrombolysis is shown if figure 3A; the AUC is 0.7 (95% CI: 0.55.0-84). The figure 3B shows the ROC curve for cortical involvement with an AUC of 0.7 (95% CI: 0.57-0.81) and figure 3C for thrombolysis with a AUC of 0.69 (95% CI: 0.55-0.82).

Discussion:

We found an incidence of 1.2% of seizures within the first 7 days after ischemic stroke, which is lower than the previously reported 4.2% of the ischemic subgroup reported by Beghi et al. [4], and clearly lower than electrical seizure patterns identified during continuous EEG monitoring in such patients reported by our group[18]. As opposed to previous studies in this field[2,3,4,5], we limited our analysis exclusively to ischemic stroke and in acute phase. The higher incidence in most previous studies focusing on acute seizure ranging from 1.2% to 6.3%[4,19,20,21,22] may partially be explained by the inclusion of intracerebral hemorrhages.

The other principal finding of our results is the association of acute seizures with thrombolysis with rt-PA. Indeed, patients receiving recombinant tissue plasminogen

activator (rt-PA) have an OR for seizure occurrence of 4.6 after correction for the main confounding factors. This was not explained by symptomatic or radiological hemorrhagic transformation as a seizure trigger or sign of reperfusion injury. One hypothetical explanation may be recanalisation with free radical production and reperfusion injury that may trigger seizures, even in the absence of haemorrhage. A small series[23] described dramatic neurological recovery after seizures appearing during the thrombolysis with rt-PA. The authors argued that the seizures might be a sign of early recanalisation and thus, of a good outcome[24]. However, in our study, recanalization was not associated with seizure occurrence in multivariated analysis.

A further and probably more likely explanation could be related to the rt-PA itself, which is known to be neurotoxic in vitro with a large amount of evidence recently reviewed[8]. Moreover, this molecule has also been implicated in epileptogenesis in animal model[9,25,26]. This supports the probable role of rt-PA as of seizure facilitator in acute ischemic stroke, and could corroborate the advantage of thrombolytic agents without neurotoxic effect[27]. Moreover it is interesting to note that seizures were not reported as side effects in the randomized studies that established the efficacy of rt-PA for ischemic stroke[28,29,30].

Toxicity of iodine contrast did not play a role in seizure induction in our cohort: 70% of patients with seizure received contrast and 81% did in the control group (p=0.27).

As previously known, cortical involvement seems to represent the strongest predictor of seizure occurrence [2,4], this association also occurs with other brain pathologies such as trauma[31], and tumor[32]. In our view this reflect the importance of the neocortex in seizure genesis[33].

Concerning stroke etiology and in contrast to previous studies[7],[34], our data do not suggest that cardiac sources represent an independent relevant factor. However, lacunar infarct was completely absent in the seizure group, reinforcing the role of cortical involvement in seizure genesis.

Higher total cholesterol level have been previously described to be "protective" from seizure[4],[19]. In this regard, neurosteroids, derived from cholesterol, are known to have an anticonvulsant and antiepileptogenic activities[35]. Moreover, lower cholesterol levels are associated with greater risk for symptomatic hemorrhagic transformation after recanalisation therapy for ischemic stroke[36]. Our data do not confirm the "protective" effect of hypercholesterolemia or prestroke statin use against acute seizure, perhaps because of its marginal effect and limited number of cases.

As discussed in a comprehensive review[1], seizure in the acute stroke setting do probably not influence short and long-term outcome when corrected for confounding factors in patients without thombolytic treatments. Our study shows a trend to a less favorable outcome for patients with seizures; this is possibly explained by the markedly higher median NIHSS on admission of these patients (14.8; IQR: 15 vs. 7; IQR: 13, $p<0.01$) in the whole groups. As seizure, in this setting, is a stroke manifestation, it appears logical that the outcome is mainly predicted by the brain damage itself. However in the subgroup analysis of thrombolysed patients only, occurrence of seizure is associated with worse outcome at 3 month without any difference in NIHSS on admission nor in the symptomatic hemorrhagic transformation rate. This finding could have some possible direct implications. Indeed as rt-PA is clearly associated with seizures and as their occurrence worsen the outcome in the thrombolysed patients, the use of another thrombolytic agent could be interesting.

Our results show that neither previous seizures, nor the premorbid use of anti-epileptic drugs or alcohol abuse has any effect in seizure prediction.

The limitations of our study are its partially retrospective nature of cases' identification and data collection, which may lead to underascertainment; however, at our center all stroke patients with a clinical suspicion of in- or out-of-hospital seizures undergo an EEG, including on weekends. Even if the seizure incidence was possibly underestimated, we believe that this did not influence the comparison of groups. The relatively low incidence may be also explained by our inclusion criteria (only acute setting and after ischemic stroke). The relatively low number of patients with seizures limited the power of the study to identify other, less important predictors. We also did not analyze the recurrence of seizure after the initial 7 days and therefore cannot say whether acute phase seizures after ischemic stroke predispose to further seizures later on. Finally, our study shows an association between thrombolysis and acute seizures, which do not mean causality.

In conclusion, acute seizure in ischemic stroke seems relatively infrequent and the cortical involvement is the principal risk factor. Our results also show that thrombolysis with rt-PA may increase the likelihood of epileptic seizures in the acute phase of ischemic stroke, independently from recanalization or symptomatic intracerebral hemorrhage. The outcome seems negatively influenced by seizure occurrence in thrombolysed patients only. This supports in our view the use of non-epileptogenic thrombolytic agent. In the future, seizures in thrombolysed patients should be assessed prospectively in acute but also in delayed phase. Indeed, post-stroke epilepsy increases morbidity of stroke. If this association is confirmed in chronic phase, "non-epileptogen" thrombolytic agent should be even more preferred.

Disclosures:

- Vincent Alvarez: nothing to disclose
- Andrea O. Rossetti: research support: Pfizer, UCB, Sandoz, EISAI, and GSK
- Patrik Michel: research support: Lundbeck Europe, consulting: Lundbeck Europe, Boehringer-Ingelheim, Bayer

<u>References:</u>

1. Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. *Drugs & aging*. 2004;21:639-653.

2. Bladin CF, Alexandrov AV, Bellavance A, et al. Seizures after stroke: a prospective multicenter study. *Arch neurol*. 2000;57:1617-1622.

3. Kammersgaard LP, Olsen TS. Poststroke epilepsy in the Copenhagen stroke study: incidence and predictors. *J Stroke Cerebrovasc Dis*. 2005;14:210-214.

4. Beghi E, D'Alessandro R, Beretta S, et al. Incidence and predictors of acute symptomatic seizures after stroke. *Neurology*. 2011;77:1785-1793.

5. Herdt V De, Dumont F, Hénon H, et al. Early seizures in intracerebral hemorrhage: Incidence, associated factors, and outcome. *Neurology*. 2011;77:1794-1800.

6. Arboix A, García-Eroles L, Massons JB, Oliveres M, Comes E. Predictive factors of early seizures after acute cerebrovascular disease. *Stroke*. 1997;28:1590-1594.

7. Giroud M, Gras P, Fayolle H, et al. Early seizures after acute stroke: a study of 1,640 cases. *Epilepsia*. 1994;35:959-64.

8. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. *Trends Neurosci*. 2009;32:48-55.

9. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. *Nature*. 1993;361:453-457.

10. Iyer AM, Zurolo E, Boer K, et al. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. *Neuroscience*. 2010;167:929-945.

11. Michel P, Odier C, Rutgers M, et al. The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging. *Stroke*. 2010;41:2491-2498.

12. Fisher RS, Boas WVE, Blume W, et al. Epileptic Seizures and Epilepsy : Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia*. 2005;46:470-472.

13. Berg A, Berkovic S, Brodie M, Buchhalter J. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology , 2005 – 2009. *Epilepsia*. 2010;51:676-685.

14. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke*. 1993;24:35-41.

15. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. *Cerebrovasc Dis*. 2008;25:457-507.

16. Michel P, Arnold M, Hungerbühler H-jörg, et al. Thrombolyse de l'attaque cérébrale ischémique: recommandations actualisées. *Swiss Medical Forum*. 2006;6:225-228.

17. Larrue V, Kummer R von, Muller a, Bluhmki E. Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II). *Stroke*. 2001;32:438-441.

18. Carrera E, Michel P, Despland P-A, et al. Continuous assessment of electrical epileptic activity in acute stroke. *Neurology*. 2006;67:99-104.

19. Devuyst G, Karapanayiotides T, Hottinger I. Prodromal and early epileptic seizures in acute stroke: Does higher serum cholesterol protect? *Neurology*. 2003;61:249-252.

20. Labovitz DL, Hauser WA, Sacco RL. Prevalence and predictors of early seizure and status epilepticus after first stroke. *Neurology*. 2001;57:200-206.

21. Burn J, Dennis M, Bamford J, et al. Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. *BMJ*. 1997;315:1582-1587.

22. Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. *Neurology*. 1978;28:754-762.

23. Rodan LH, Aviv RI, Sahlas DJ, et al. Seizures during stroke thrombolysis heralding dramatic neurologic recovery. *Neurology*. 2006;67:2048-2049.

24. Wunderlich MT, Goertler M, Postert T, et al. Recanalization after intravenous thrombolysis: does a recanalization time window exist? *Neurology*. 2007;68:1364-1368.

25. Yepes M, Sandkvist M, Coleman TA, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. *J Clin Invest*. 2002;109:1571-1578.

26. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. *Nature*. 1995;377:340-344.

27. Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. *Expert Opin Biol Ther*. 2009;9:773-778.

28.Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med*. 1995;333:1581-1587.

29. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). *JAMA*. 1995;274:1017-1025.

30. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke (ECASS-III). *N Engl J Med*. 2008;359:1317-1329.

31. Englander J, Bushnik T, Duong TT, et al. Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. *Arch Phys Med Rehabil*. 2003;84:365-373.

32. Breemen MSM van, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. *Lancet neurol*. 2007;6:421-430.

33. Connors BW. Initiation of synchronized neuronal bursting in neocortex. *Nature*. 1984;310:685-687.

34. Bentes C, Pimentel J, Ferro JM. Epileptic seizures following subcortical infarcts. *Cerebrovasc Dis*. 2001;12:331-334.

35. Biagini G, Panuccio G, Avoli M. Neurosteroids and epilepsy. *Curr Opin Neurol*. 2010; 23: 170-176.

36. D'Amelio M, Terruso V, Famoso G, et al. Cholesterol levels and risk of hemorrhagic transformation after acute ischemic stroke. *Cerebrovasc Dis*. 2011; 32: 234-238.

Tables & Figures:

Tables:

Table 1: Type of seizure according to acute stroke treatment

	Thrombolysed patients n=12		Not Thrombolysed patients n=16		P value (test)
	n	%	n	%	
Focal without impairment of consciousness	2	16.7	1	6.3	0.61 (χ2)
Focal with impairment of consciousness	3	25	6	37.5	
Generalized convulsive	4	33.3	7	43.7	
Status epilepticus	3	25	2	12.5	

Table 2: Comparison of seizure group (excluding patients with seizure at stroke onset) and control group

	Seizure group n=20		Control group n=100		p value (test)
	n, median (IQR) or mean (SD)	% or range	n, median (IQR) or mean (SD)	% or range	
Patients characteristics:					
Age (median and IQR)	0	18-86	70.9 (18.5)	24-93	0.37 (t)
Male gender	10	50	59	59	0.45 (χ2)
OH abuse	2	10	7	7	0.92 (Fisher)
Previous seizures	1	5	4	4	0.99 (Fisher)
Previous clinical stroke					
Ischemic	6	30	28	28	
Hemorrhagic	0	0	1	1	
None	14	70	71	71	0.89 (Fisher)
Pre-stroke treatment					
Statin	5	25	24	24	0.92 (χ2)
Benzodiazepine	2	10	10	10	0.59 (Fisher)
Anti-epileptic drugs	1	5	4	4	0.99 (Fisher)
Admission metabolic values (mean and SD)**:**					
Glucose value (mmol/l)	6.48 (1.0)	5.1-7.9	7.7[a] (2.8)	4-19	0.07 (t)
Na+ (mmol/l)	140 (3.71)	129-145	141 (3.0)	131-140	0.67 (t)
Cholesterol (mmol/l)	5.1[b] (1.1)	3.4-7.6	5.51[c](1.8)	2.6-15.8	0.31 (t)
Stroke characteristics & treatment:					
Stroke localization					
Involving cortex	18	90	50	50	<0.01 (Fisher)
Stroke Etiology					
Atherosclerosis (with ≥50% stenosis)	4	20	20	20	
Cardiac	7	35	29	29	
Lacunar	0	0	14	14	
Arterial dissection	1	5	5	5	
Multiple/coexisting	1	5	7	7	
Unknown/rare	7	35	25	25	0.58 (χ2)
Stroke onset					
Known	12	60	53	53	
Approximately known (+/- 1h)	2	10	20	20	
During sleep	3	15	22	22	

Unknown but <24h	3	15	5	5	0.26 (χ2)
NIHSS on admission (median and IQR)	14.8 (15)	1-32	9.35(13)	0-33	<0.01 (t)
CT with contrast	14	70	81	81	0.26 (χ2)
Thrombolysis with rt-PA	11	55	18	18	<0.01 (χ2)
Complete or partial recanalisation after documented occlusion	9	45	15	15	<0.01 (χ2)
Symptomatic hemorrhagic transformation	1	5	6	6	0.99 (Fisher)
Radiologic hemorrhagic transformation when documented	7[d]	39	10[e]	19.3	0.094 (χ2)

a = 99 values/100; b= 17 values/20; c= 90 values/100; d=18 available/20; e=52 available/100

Table 3: Comparison of clinical outcome of seizure and control group:

ALL PATIENTS:					
	Seizure group n=28		Control group n=100		p value (test)
Clinical outcome					
mRS ≥3 at 7 days	17	60.7	48	48	0.23 (χ2)
mRS ≥3 at 3 months	16	57.2	39	39	0.09 (χ2)
Death at 3 months	6	21.4	18	18	0.68 (χ2)
THROMBOLYSED PATIENTS ONLY:					
	Seizure group n=12		Control group n=18		p value (test)
Clinical outcome					
mRS ≥3 at 7 days	10	83.3	11	61.1	0.37 (Fisher)
mRS ≥3 at 3 months	9	75	6	33.3	0.02 (χ2)
Death at 3 months	2	16.6	4	22.2	0.99 (Fisher)

Figures:

Figure 1: Time of seizure occurrence within the first 7 days after acute ischemic stroke

Figure 2: Type of Seizure according to the ILAE classification[13]

Figure 3: ROC curves for the different variables included in the regression model
   A) **For the model including "Cortical involvement" and "thrombolysis"; AUC: 0.7 (95% CI: 0.55-0.84)**
   B) **For the variable "Cortical involvement"; AUC: 0.7 (95% CI: 0.59.0-81)**
   C) **For the variable "Thrombolysis"; AUC: 0.69 (95% CI: 0.55-0.82)**

	At stroke onset	0.1-24h	25-48h	49-72h	>72h
	28.6% n=8	35.7% n=10	25% n=7	10.7% n=3	0

A.

B.

C.